Dr. Chapa’s Clinical Pearls.

GLP1 Agonist Exposure in Pregnancy

03.05.2024 - By Dr. Chapa’s Clinical PearlsPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Use of second-line noninsulin diabetic medications, like Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors, is rapidly increasing for treatment of T2D and other indications. As these drugs are being used by an increasing group of fertile women, it is expected that a few of them will get pregnant and data on their safety when used in the first trimester is needed. Is periconceptional use of glucagon-like peptide 1 (GLP-1) receptor agonists associated with increased risk of major congenital malformations? In this episode, we will look at the available data (although limited) regarding these medications, focusing on specific GLP1 options.

More episodes from Dr. Chapa’s Clinical Pearls.